Cerebrolysin

Background

Cerebrolysin is a parenteral neuropeptide complex consisting of low‑molecular‑weight peptides and free amino acids produced by enzymatic digestion of purified porcine brain proteins.[11][15] It is often described as a neurotrophic factor–mimetic preparation because its peptide components exhibit biological activities similar to endogenous neurotrophins in preclinical models.[11][14][15]

The product was developed in the late 20th century and is manufactured by EVER Pharma (formerly Ebewe). It has been in clinical use for several decades in parts of Europe and Asia, particularly in the Russian Federation, Eastern Europe, and China, where it is widely used for acute ischemic stroke, traumatic brain injury (TBI), and various neurodegenerative or cognitive disorders.[11][15] It is not structurally a single defined peptide but an undefined mixture in which peptide fractions <10 kDa predominate.[11][15]

Synonyms and descriptors in the literature include “porcine brain‑derived peptide preparation”, “neurotrophic peptide mixture”, and “Cerebrolysin®” as the trade name.[11][15]

Mechanism of action

Because Cerebrolysin is a heterogeneous peptide mixture, its mechanism of action is inferred primarily from in vitro and animal studies:

• Neurotrophic factor–like activity: Cerebrolysin has been reported to mimic or enhance the actions of endogenous neurotrophins such as nerve growth factor (NGF), brain‑derived neurotrophic factor (BDNF), and glial cell line–derived neurotrophic factor (GDNF).[11][14] This includes promotion of neuronal survival, neurite outgrowth, and synaptic plasticity in various models.[14]

• Neuroprotection in ischemia and injury: In rodent models of focal cerebral ischemia, post‑ischemic administration of Cerebrolysin (e.g., 2.5 mL/kg intraperitoneally starting 24 h after middle cerebral artery occlusion) reduces apoptotic cell death in peri‑infarct regions and improves neurological function, despite modest or absent reduction in infarct volume.[14] Reduced TUNEL‑positive cells (~50% reduction) in the ischemic boundary suggests anti‑apoptotic effects.[14]

• Promotion of neurogenesis and plasticity: Experimental stroke models show increased proliferation of neural progenitor cells in the subventricular zone and enhanced migration of neuroblasts toward the ischemic boundary after Cerebrolysin treatment, with associated improvements in behavioral tests.[14]

• Anti‑inflammatory and anti‑excitotoxic actions (preclinical): Various in vitro and in vivo studies (not all large or standardized) have reported attenuation of glutamate toxicity, modulation of microglial activation, and reduction of oxidative stress markers, consistent with a broad cytoprotective profile.[11][14]

• Vascular and blood–brain barrier (BBB) effects: In the context of acute ischemic stroke and thrombolysis, mechanistic hypotheses include stabilization of the BBB and reduction of hemorrhagic transformation risk, potentially via trophic effects on endothelial cells and modulation of matrix metalloproteinases.[13]

The preparation does not correspond to a single receptor agonist; instead, it is presumed to act via multiple receptor systems involved in neurotrophin signaling (e.g., Trk and p75 receptors), intracellular survival pathways (PI3K/Akt, MAPK/ERK), and plasticity‑related gene expression, though direct receptor binding data for the mixture are limited and not fully defined.[11][14]

Evidence summary

Traumatic brain injury (TBI)

A 2023 systematic review and meta‑analysis of Cerebrolysin in TBI (Yao et al., 2023) included randomized controlled trials and observational studies evaluating functional outcome and mortality.[11][12] The review concluded that Cerebrolysin may improve functional recovery and reduce mortality compared with standard care, but the evidence quality was variable and many studies were small or had methodological limitations.[11][12]

The meta‑analysis reported:

• Improvement in Glasgow Outcome Scale or extended scales in several trials; pooled analyses indicated a statistically significant benefit in functional outcome at follow‑up, although heterogeneity was substantial.[11][12]
• Some studies suggested reduced mortality with Cerebrolysin, but confidence intervals were wide, and risk of bias (including funding and blinding issues) was non‑trivial.[11][12]

Overall, the TBI evidence base supports potential benefit, but is constrained by limited sample sizes and varying study quality.

Acute ischemic stroke

A Cochrane review (Zhang et al., 2017 update) analyzing randomized controlled trials of Cerebrolysin in acute ischemic stroke identified seven trials with 1601 participants.[15] The main findings were:

• No clear evidence of a reduction in all‑cause mortality at 90 days.
• No convincing evidence of substantial benefit on dependency or disability scales (e.g., modified Rankin Scale, Barthel Index), although some individual trials reported positive effects on certain secondary functional or neurological endpoints.[15]
• Trials were frequently at unclear or high risk of bias; many were at least partially sponsored by the manufacturer.[15]

The review concluded that existing trials are insufficient to support or refute a clinically important benefit of Cerebrolysin in acute ischemic stroke and called for large, high‑quality, independent RCTs.[15]

A more recent post hoc analysis of the CEREHETIS trial evaluated heterogeneous treatment effects of early Cerebrolysin as an add‑on to intravenous thrombolysis (IVT) in patients with acute ischemic stroke.[13] In CEREHETIS, patients received standard IVT with or without Cerebrolysin; the post hoc modeling (n ≈ 220) suggested that Cerebrolysin reduced hemorrhagic transformation and improved functional outcomes predominantly in patients with moderate or high baseline risk of hemorrhagic transformation, while little effect was seen in low‑risk patients.[13] These findings are exploratory, hypothesis‑generating, and not definitive efficacy evidence.

Preclinical stroke and neurodegeneration models

In a rat model of transient middle cerebral artery occlusion, daily Cerebrolysin at 2.5 mL/kg for 10 days, started 24 h after ischemia, significantly improved neurological scores and sensorimotor performance without clear reduction in infarct volume.[14] Treatment was associated with enhanced neurogenesis in the subventricular zone and increased neuroblast migration toward the infarct.[14]

Other preclinical work has examined Cerebrolysin in models of Alzheimer’s disease, Parkinson’s disease, and chronic cerebral hypoperfusion; many of these studies report improvements in learning and memory, synaptic markers, or amyloid‑related pathology, but they are heterogeneous and largely preclinical or early‑phase, with limited confirmatory human data.[9][11]

Other indications

Clinical studies of Cerebrolysin in vascular dementia, Alzheimer’s disease, and post‑stroke cognitive impairment have been conducted, typically with sample sizes in the low hundreds, and often report modest improvements on cognitive scales (e.g., Mini‑Mental State Examination, Alzheimer’s Disease Assessment Scale–Cognitive Subscale). These data are not uniformly positive, and many studies are single‑center or manufacturer‑supported; high‑quality phase 3 evidence with robust functional endpoints remains limited.[11][15]

Clinical and research uses

Approved and routine uses outside US/EU

In several countries in Eastern Europe and Asia (e.g., Russia, Ukraine, China), Cerebrolysin has national approvals or is included in local treatment guidelines as an adjunctive therapy for:

• Traumatic brain injury (moderate to severe) as part of neurorehabilitation.[11][12]
• Acute ischemic stroke, usually initiated within the first days after onset.[11][15]
• Vascular or degenerative dementias and other cognitive disorders, typically in cyclic treatment courses.[11]

Regulatory dossiers underlying these national approvals are not harmonized with FDA/EMA standards and often rely on regional trial data.

Investigational and off‑label contexts

In Western settings, Cerebrolysin is used mainly in clinical research or off‑label in private practice:

• As an add‑on to reperfusion therapy in acute ischemic stroke (e.g., CEREHETIS and related mechanistic studies).[13]
• As a neurorehabilitation adjuvant following TBI or stroke, with endpoints including functional independence, cognitive performance, and quality of life.[11][12]
• In exploratory studies of Alzheimer’s disease and mild cognitive impairment, sometimes in combination with other agents, focusing on cognitive scales and global clinical impression.[11]

No major professional society guidelines in the US or EU endorse routine use of Cerebrolysin, reflecting limited high‑quality trial evidence and lack of centralized approval.

Dosing context

Cerebrolysin is administered parenterally, most often by intravenous infusion, with dosing regimens varying by indication and region. The following ranges reflect reported research protocols, not prescribing recommendations:

• Acute ischemic stroke: Clinical trials have commonly used 10–50 mL/day IV, diluted in 100–250 mL of normal saline, administered once daily for 10–21 days, initiated within the first 24–72 h of stroke onset.[13][15]

• Traumatic brain injury: TBI studies generally employ 10–50 mL/day IV for 10–20 days, sometimes followed by additional intermittent courses during rehabilitation.[11][12]

• Dementia and cognitive disorders: Regimens in dementia trials include 10–30 mL/day IV or IM for 10–28 days, often repeated in cycles separated by weeks or months.[11]

Dose is usually expressed as volume of the standardized solution (often 215.2 mg/mL of peptide fraction), but exact composition in mg/kg is not consistently reported in clinical trials.[11][15]

Safety profile

Across clinical trials and post‑marketing reports from countries where it is widely used, Cerebrolysin is generally described as well tolerated, with most adverse events (AEs) being mild and transient.[11][12][15]

Frequently reported AEs include:[11][12][15]

• Local injection‑site reactions (pain, erythema).
• Transient dizziness, headache, or agitation.
• Mild fever or flu‑like symptoms.
• Gastrointestinal symptoms such as nausea.

Serious adverse events (SAEs) have been reported, but rates are usually similar between Cerebrolysin and placebo in randomized trials, making attribution uncertain.[15] In stroke trials, causes of death have included cerebral infarct, heart failure, pulmonary embolism, and pneumonia, occurring in both Cerebrolysin and placebo groups; no consistent pattern of drug‑specific mortality signal has been demonstrated.[15]

Allergic or hypersensitivity reactions appear rare but are biologically plausible given its porcine protein origin; detailed incidence data are limited.[11]

Long‑term safety data from large, independently monitored cohorts are sparse. There is limited information on carcinogenicity, reproductive toxicity, or detailed immunogenicity, reflecting its status as a legacy biological preparation rather than a newly registered biologic.

Regulatory status

• United States: Cerebrolysin is not approved by the US Food and Drug Administration (FDA) for any indication. It is not listed among FDA‑licensed biological products or approved new drugs, and its use in the US is restricted to clinical research under appropriate regulatory oversight.

• European Union / European Economic Area: Cerebrolysin does not have a centralized marketing authorization from the European Medicines Agency (EMA). However, it is marketed in several individual European countries based on national approvals, primarily in Eastern and Central Europe, where it is classified as a neurotropic or nootropic medicinal product for stroke, TBI, and cognitive impairment.[11][15]

• Other regions: The drug is approved and widely used in Russia, parts of Eastern Europe, and various Asian countries (including China) for indications such as stroke, TBI, and dementia, with country‑specific labeling and reimbursement frameworks.[11][15]

Given the lack of FDA and EMA centralized approval and the heterogeneity of the clinical evidence, Cerebrolysin is best characterized as a regionally approved neuropeptide complex with investigational status in many high‑regulation jurisdictions, and with an evidence base that remains mixed and of moderate overall quality.